Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics ...
MDR-001 progressed from program discovery to Phase III in just 4.5 years, much faster than traditional development cycles.Phase IIb data ...
LQT-23 is a potent, highly differentiated, first-in-class allosteric small molecule inhibitor of MSH3/MutSß Unique mechanism of action with potential to slow or stop ...
Small molecule drugs dominate new drug approvals and are crucial for treating diverse diseases. They are typically low-weight, providing easy absorption and versatile delivery methods. Their simpler ...
Vietnam Investment Review on MSN
Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it recently received the Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the Phase II ...
Tv Therapeutics (VTVT) is a $156 million biopharma focused on small molecule drugs for Alzheimer’s, diabetes, and ...
Small Molecule CMO/CDMO Market Report On Size, Share, Competitive Landscape, And Trends Analysis. EINPresswire/ -- The small molecule CMO/CDMO sector is experiencing robust growth fueled by evolving ...
WASHINGTON, DC - AUGUST 16: U.S. President Joe Biden (C) signs The Inflation Reduction Act with Senate Majority Leader Charles Schumer (D-NY) (L) and House Majority Whip James Clyburn (D-SC) in the ...
In opposing a fix to the 2022 Inflation Reduction Act, a leading voice in the effort to move the U.S. biopharmaceutical system toward European-style price controls cited “complicated details” in his ...
The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback